Human immunodeficiency virus 1 (HIV-1) infection remains a public health concern globally. Although great strides in the management of HIV-1 have been achieved, current highly active antiretroviral therapy is limited by multidrug resistance, prolonged use-related effects, and inability to purge the HIV-1 latent pool. Even though novel therapeutic options with HIV-1 broadly neutralizing antibodies (bNAbs) are being explored, the scalability of bNAbs is limited by economic cost of production and obligatory requirement for parenteral administration. However, these limitations can be addressed by antibody mimetics/peptidomimetics of HIV-1 bNAbs. In this review we discuss the limitations of HIV-1 bNAbs as HIV-1 entry inhibitors and explore the potential therapeutic use of antibody mimetics/peptidomimetics of HIV-1 entry inhibitors as an alternative for HIV-1 bNAbs. We highlight the reduced cost of production, high specificity, and oral bioavailability of peptidomimetics compared to bNAbs to demonstrate their suitability as candidates for novel HIV-1 therapy and conclude with some perspectives on future research toward HIV-1 novel drug discovery.
(UNAIDS) JUNPoHA. Global HIV & AIDS statistics: 2019 fact sheet. Geneva, Switzerland: Author, 2020
2.
SankarananthamM.HIV - is a cure possible?Indian J Sex Transm Dis AIDS2019;
40:1–5
3.
GünthardHFSaagMSBensonCAdel RioCEronJJGallantJEHoyJFMugaveroMJSaxPEThompsonMAGandhiRTLandovitzRJSmithDMJacobsenDMVolberdingPA.Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral Society-USA panel. JAMA2016;
316:191–210
4.
KaufmannDERosenbergES.The value of preserving HIV-specific immune responses. J HIV Ther2003;
8:19–25
5.
ChesneyMAMorinMSherrL.Adherence to HIV combination therapy. Soc Sci Med2000;
50:1599–605
6.
StolkLMLüersJF.Increasing number of anti-HIV drugs but no definite cure. Review of anti-HIV drugs. Pharm World Sci2004;
26:133–6
7.
VanhamelJBruggemansADebyserZ.Establishment of latent HIV-1 reservoirs: what do we really know?J Virus Erad2019;
5:3–9
8.
BroderS.The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res2010;
85:1–18
9.
GulickRMLalezariJGoodrichJClumeckNDeJesusEHorbanANadlerJClotetBKarlssonAWohlfeilerMMontanaJBMcHaleMSullivanJRidgwayCFelsteadSDunneMWvan der RystEMayerH.Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med2008;
359:1429–41
10.
HenrichTJKuritzkesDR.HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol2013;
3:51–7
11.
FätkenheuerGNelsonMLazzarinAKonourinaIHoepelmanAILampirisHHirschelBTebasPRaffiFTrottierBBellosNSaagMCooperDAWestbyMTawadrousMSullivanJFRidgwayCDunneMWFelsteadSMayerHvan der RystE.Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med2008;
359:1442–55
12.
LazzarinAClotetBCooperDReynesJArastéhKNelsonMKatlamaCStellbrinkHJDelfraissyJFLangeJHusonLDeMasiRWatCDelehantyJDrobnesCSalgoM.Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med2003;
348:2186–95
13.
LiuYCaoWSunMLiT.Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerg Microbes Infect2020;
9:194–206
14.
MorrowTFelconeLH.Defining the difference: what makes biologics unique. Biotechnol Healthc2004;
1:24–9
15.
VllasaliuDThanouMStolnikSFowlerR.Recent advances in the oral delivery of biologics: nanomedicine and physical modes of delivery. Expert Opin Drug Deliv2018;
15:759–70
16.
ZhangXDiraviyamT.Antibody mimetics, peptides, and peptidomimetics. Methods Mol Biol2017;
1575:3–13
17.
MabongaLKappoAP.Peptidomimetics: a synthetic tool for inhibiting protein–protein interactions in cancer. Int J Pept Res Ther2020;
26:225–41
18.
VagnerJQuHHrubyVJ.Peptidomimetics, a synthetic tool of drug discovery. Curr Opin Chem Biol2008;
12:292–6
RobertsAWStilgenbauerSSeymourJFHuangDCS.Venetoclax in patients with previously treated chronic lymphocytic leukemia. Clin Cancer Res2017;
23:4527–33
23.
AwiNJTeowSY.Antibody-mediated therapy against HIV/AIDS: where are we standing now?J Pathog2018;
2018:1–9
24.
GallayP.Syndecans and HIV-1 pathogenesis. Microbes Infect2004;
6:617–22
25.
ArthosJCicalaCMartinelliEMacleodKVan RykDWeiDXiaoZVeenstraTDConradTPLempickiRAMcLaughlinSPascuccioMGopaulRMcNallyJCruzCCCensoplanoNChungEReitanoKNKottililSGoodeDJFauciAS.HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol2008;
9:301–9
26.
GeijtenbeekTBKwonDSTorensmaRvan VlietSJvan DuijnhovenGCMiddelJCornelissenILNottetHSKewalRamaniVNLittmanDRFigdorCGvan KooykY.DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell2000;
100:587–97
27.
KwongPDWyattRRobinsonJSweetRWSodroskiJHendricksonWA.Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature1998;
393:648–59
28.
TomarasGDGreenbergML.Mechanisms for HIV-1 entry: current strategies to interfere with this step. Curr Infect Dis Rep2001;
3:93–9
29.
MelikyanGBMarkosyanRMHemmatiHDelmedicoMKLambertDMCohenFS.Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol2000;
151:413–23
30.
ChenB.Molecular mechanism of HIV-1 entry. Trends Microbiol2019;
27:878–91
31.
Venanzi RulloECeccarelliMCondorelliFFacciolàAVisalliGD'AleoFPaolucciICacopardoBPinzoneMR, DRosaMNunnariGPellicanòGF.Investigational drugs in HIV: pros and cons of entry and fusion inhibitors (review). Mol Med Rep2019;
19:1987–95
32.
RaySFatimaZSaxenaA.Drugs for AIDS. Mini Rev Med Chem2010;
10:147–61
33.
LobritzMARatcliffANArtsEJ.HIV-1 entry, inhibitors, and resistance. Viruses2010;
2:1069–105
34.
QianKMorris-NatschkeSLLeeKH.HIV entry inhibitors and their potential in HIV therapy. Med Res Rev2009;
29:369–93
35.
IacobSAIacobDG.Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy. Front Microbiol2017;
8:2323
36.
BlairHA.Ibalizumab: a review in multidrug-resistant HIV-1 infection. Drugs2020;
80:189–96
37.
MarkhamA.Ibalizumab: first global approval. Drugs2018;
78:781–5
38.
JacksonGGPerkinsJTRubenisMPaulDAKniggeMDespotesJCSpencerP.Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet1988;
2:647–52
39.
KarpasAHewlettIKHillFGrayJByronNGilgenDBallyVOatesJKGazzardBEpsteinJE.Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci U S A1990;
87:7613–7
40.
JaworskiJPVendrellAChiavennaSM.Neutralizing monoclonal antibodies to fight HIV-1: on the threshold of success. Front Immunol2016;
7:661
41.
HuangJOfekGLaubLLouderMKDoria-RoseNALongoNSImamichiHBailerRTChakrabartiBSharmaSKAlamSMWangTYangYZhangBMiguelesSAWyattRHaynesBFKwongPDMascolaJRConnorsM.Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature2012;
491:406–12
42.
StephensonKEBarouchDH.Broadly neutralizing antibodies for HIV eradication. Curr HIV/AIDS Rep2016;
13:31–7
ShcherbakovDNBakulinaAYKarpenkoLIIlyichevAA.Broadly neutralizing antibodies against HIV-1 as a novel aspect of the immune response. Acta Naturae2015;
7:11–21
45.
ScheidJFMouquetHFeldhahnNWalkerBDPereyraFCutrellESeamanMSMascolaJRWyattRTWardemannHNussenzweigMC.A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods2009;
343:65–7
46.
WuXYangZYLiYHogerkorpCMSchiefWRSeamanMSZhouTSchmidtSDWuLXuLLongoNSMcKeeKO'DellSLouderMKWycuffDLFengYNasonMDoria-RoseNConnorsMKwongPDRoedererMWyattRTNabelGJMascolaJR.Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science2010;
329:856–61
47.
SimekMDRidaWPriddyFHPungPCarrowELauferDSLehrmanJKBoazMTarragona-FiolTMiiroG.Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol2009;
83:7337–48
48.
McCoyLEBurtonDR.Identification and specificity of broadly neutralizing antibodies against HIV. Immunol Rev2017;
275:11–20
49.
HessellAJRakaszEGPoignardPHangartnerLLanducciGForthalDNKoffWCWatkinsDIBurtonDR.Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog2009;
5:e1000433
50.
CaskeyMKleinFLorenziJCSeamanMSWestAPBuckleyNKremerGNogueiraLBraunschweigMScheidJFHorwitzJAShimeliovichIBen-AvrahamSWitmer-PackMPlattenMLehmannCBurkeLAHawthorneTGorelickRJWalkerBDKelerTGulickRMFätkenheuerGSchlesingerSJNussenzweigMC.Corrigendum: viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature2015;
522:487–91
51.
Halper-StrombergALuCLKleinFHorwitzJABournazosSNogueiraLEisenreichTRLiuCGazumyanASchaeferUFurzeRCSeamanMSPrinjhaRTarakhovskyARavetchJVNussenzweigMC.Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell2014;
158:989–99
52.
HorwitzJAHalper-StrombergAMouquetHGitlinADTretiakovaAEisenreichTRMalbecMGravemannSBillerbeckEDornerMBüningHSchwartzOKnopsEKaiserRSeamanMSWilsonJMRiceCMPlossABjorkmanPJKleinFNussenzweigMC.HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A2013;
110:16538–43
53.
KleinFHalper-StrombergAHorwitzJAGruellHScheidJFBournazosSMouquetHSpatzLADiskinRAbadirAZangTDornerMBillerbeckELabittRNGaeblerCMarcovecchioPIncesuRBEisenreichTRBieniaszPDSeamanMSBjorkmanPJRavetchJVPlossANussenzweigMC.HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature2012;
492:118–22
54.
LuRMHwangYCLiuIJLeeCCTsaiHZLiHJWuHC.Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci2020;
27:1–30
55.
ParrayHAShuklaSSamalSShrivastavaTAhmedSSharmaCKumarR.Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int Immunopharmacol2020;
85:1–20
56.
HardingFASticklerMMRazoJDuBridgeRB.The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs2010;
2:256–65
57.
XuWZhangLZhangYTangY.Construction and expression of a human/mouse chimeric CD19 monoclonal antibody: successful modification of a murine IgM to a chimeric IgG. Exp Ther Med2014;
7:849–54
58.
HwangWYFooteJ.Immunogenicity of engineered antibodies. Methods2005;
36:3–10
59.
KunertRReinhartD.Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol2016;
100:3451–61
60.
LeeECOwenM.The application of transgenic mice for therapeutic antibody discovery. Methods Mol Biol2012;
901:137–48
61.
ShimH.Therapeutic antibodies by phage display. Curr Pharm Des2016;
22:6538–59
62.
HammersCMStanleyJR.Antibody phage display: technique and applications. J Invest Dermatol2014;
134:1–5
63.
SieversSAScharfLWestAPJrBjorkmanPJ.Antibody engineering for increased potency, breadth and half-life. Curr Opin HIV AIDS2015;
10:151–9
64.
Le BasleYChennellPTokhadzeNAstierASautouV.Physicochemical stability of monoclonal antibodies: a review. J Pharm Sci2020;
109:169–90
65.
WangWSinghSZengDLKingKNemaS.Antibody structure, instability, and formulation. J Pharm Sci2007;
96:1–26
66.
De MuynckBNavarreCBoutryM.Production of antibodies in plants: status after twenty years. Plant Biotechnol J2010;
8:529–63
67.
LeeYJJeongKJ.Challenges to production of antibodies in bacteria and yeast. J Biosci Bioeng2015;
120:483–90
68.
SifniotisVCruzEErogluBKayserV.Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation. Antibodies (Basel)2019;
8:1–23
69.
AwwadSAngkawinitwongU.Overview of antibody drug delivery. Pharmaceutics2018;
10:83
70.
BittnerBRichterWSchmidtJ.Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs2018;
32:425–40
71.
OvacikMLinK.Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development. Clin Transl Sci2018;
11:540–52
72.
HernandezIBottSWPatelASWolfCGHospodarARSampathkumarSShrankWH.Pricing of monoclonal antibody therapies: higher if used for cancer?Am J Manag Care2018;
24:109–12
73.
SalazarGZhangNFuTMAnZ.Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines2017;
2:1–2
74.
SrinivasanSGhoshMMaitySVaradarajanR.Broadly neutralizing antibodies for therapy of viral infections. Antibody Technol J2016;
6:1–15
75.
GokhaleASSatyanarayanajoisS.Peptides and peptidomimetics as immunomodulators. Immunotherapy2014;
6:755–74
76.
GrauerAKönigB.Peptidomimetics–a versatile route to biologically active compounds. Eur J Org Chem2009;
2009:5099–111
77.
KanhaiyaKCzeizlerEGratieCPetreI.Controlling directed protein interaction networks in cancer. Sci Rep2017;
7:10327
78.
PavetVPortalMMMoulinJCHerbrechtRGronemeyerH.Towards novel paradigms for cancer therapy. Oncogene2011;
30:1–20
79.
FurqanMAkinleyeAMukhiNMittalVChenYLiuD.STAT inhibitors for cancer therapy. J Hematol Oncol2013;
6:1–11
80.
LongJSRyanKM.New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene2012;
31:5045–60
81.
JohnstonSJCarrollJS.Transcription factors and chromatin proteins as therapeutic targets in cancer. Biochim Biophys Acta2015;
1855:183–92
82.
AkramONDeGraffDJSheehanJHTilleyWDMatusikRJAhnJMRajGV.Tailoring peptidomimetics for targeting protein-protein interactions. Mol Cancer Res2014;
12:967–78
JensenCHeroldPBrunnerHR.Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov2008;
7:399–410
85.
LeiJSunLHuangSZhuCLiPHeJMackeyVCoyDHHeQ.The antimicrobial peptides and their potential clinical applications. Am J Transl Res2019;
11:3919–31
86.
FirerMAGellermanG.Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol2012;
5:1–16
87.
AndronatiSKarasevaTKryskoA.Peptidomimetics-antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications. Curr Med Chem2004;
11:1183–211
88.
MoitessierNMinouxHMaigretBChrétienFChapleuY.Synthesis of carbohydrate-based peptidomimetics as potential selective fibrinogen receptor antagonists. Lett Pept Sci1998;
5:75–8
89.
MahlapuuMHåkanssonJRingstadLBjörnC.Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol2016;
6:194
90.
MolchanovaNHansenPRFranzykH.Advances in development of antimicrobial peptidomimetics as potential drugs. Molecules2017;
22:1–60
91.
FelícioMRSilvaONGonçalvesSSantosNCFrancoOL.Peptides with dual antimicrobial and anticancer activities. Front Chem2017;
5:5
92.
HaugBEStensenWKalaajiMRekdalØSvendsenJS.Synthetic antimicrobial peptidomimetics with therapeutic potential. J Med Chem2008;
51:4306–14
93.
EttariRBovaFZappalàMGrassoSMicaleN.Falcipain-2 inhibitors. Med Res Rev2010;
30:136–67
94.
AlamA.Bioinformatic identification of peptidomimetic-based inhibitors against plasmodium falciparum antigen AMA1. Malar Res Treat2014;
2014:1–8
95.
la PorteCJ.Saquinavir, the pioneer antiretroviral protease inhibitor. Expert Opin Drug Metab Toxicol2009;
5:1313–22
96.
PorcheDJ.Saquinavir. J Assoc Nurses AIDS Care1996;
7:61–4
97.
ShenCHWangYFKovalevskyAYHarrisonRWWeberIT.Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. FEBS J2010;
277:3699–714
98.
WilliamsGCSinkoPJ.Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev1999;
39:211–38
99.
BurgerDBoydMDuncombeCFelderhofMMahanontharitARuxrungthamKUbolyamSStekMCooperDLangeJ.Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother2003;
51:1231–38
100.
YehKCDeutschPJHaddixHHesneyMHoaglandVJuWDJusticeSJOsborneBSterrettATStoneJAWoolfEWaldmanS.Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother1998;
42:332–8
101.
RandolphJTDeGoeyDA.Peptidomimetic inhibitors of HIV protease. Curr Top Med Chem2004;
4:1079–95
102.
ZeldinRKPetruschkeRA.Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother2004;
53:4–9
TurnerSRStrohbachJWTommasiRAAristoffPAJohnsonPDSkulnickHIDolakLASeestEPTomichPKBohanonMJ.Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5, 6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem1998;
41:3467–76
107.
TsantrizosYS.Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Acc Chem Res2008;
41:1252–63
108.
LvZChuYWangY.HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl)2015;
7:95–104
109.
ShamHLKempfDJMollaAMarshKCKumarGNChenCMKatiWStewartKLalRHsuABetebennerDKorneyevaMVasavanondaSMcDonaldESaldivarAWideburgNChenXNiuPParkCJayantiVGrabowskiBGrannemanGRSunEJapourAJLeonardJMPlattnerJJNorbeckDW.ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother1998;
42:3218–24
110.
FentonCPerryCM.Darunavir: in the treatment of HIV-1 infection. Drugs2007;
67:2791–801
111.
VadhadiyaPMJeanMABouzribaCTremblayTLagüePFortinSBoukouvalasJGiguèreD. Diversity-oriented synthesis of diol-based peptidomimetics as potential HIV protease inhibitors and antitumor agents. Chembiochem 2018;
19:1771–91
112.
NeffeATMeyerB.A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120. Angew Chem Int Ed Engl2004;
43:2937–40
113.
EckertDMMalashkevichVNHongLHCarrPAKimPS.Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell1999;
99:103–15
114.
WelchBDFrancisJNRedmanJSPaulSWeinstockMTReevesJDLieYSWhitbyFGEckertDMHillCPRootMJKayMS.Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol2010;
84:11235–44
115.
WelchBDVanDemarkAPHerouxAHillCPKayMS.Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A2007;
104:16828–33
116.
LinPFBlairWWangTSpicerTGuoQZhouNGongYFWangHGRoseRYamanakaGRobinsonBLiCBFridellRDeminieCDemersGYangZZadjuraLMeanwellNColonnoR.A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A2003;
100:11013–8
117.
ZhaoQMaLJiangSLuHLiuSHeYStrickNNeamatiNDebnathAK.Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology2005;
339:213–25
118.
AndrianovAMKashynIATuzikovAV.Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01. J Mol Graph Model2015;
61:262–71
119.
AndrianovAMKashynIATuzikovAV.Potential HIV-1 fusion inhibitors mimicking gp41-specific broadly neutralizing antibody 10E8: in silico discovery and prediction of antiviral potency. J Bioinform Comput Biol2018;
16:1840007
120.
MuraliRGreeneMI.Structure based antibody-like peptidomimetics. Pharmaceuticals (Basel)2012;
5:209–35
121.
ChikaevANBakulinaAYBurdickRCKarpenkoLIPathakVKIlyichevAA.Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01. PLoS One2015;
10:e0120847
122.
KuzminaAVakninKGdalevskyGVyazmenskyMMarksRSTaubeREngelS.Functional mimetics of the HIV-1 CCR5 co-receptor displayed on the surface of magnetic liposomes. PLoS One2015;
10:e0144043
123.
RichardJVeilletteMBrassardNIyerSSRogerMMartinLPazgierMSchönAFreireERoutyJPSmithAB3rdParkJJonesDMCourterJRMelilloBNKaufmannDEHahnBHPermarSRHaynesBFMadaniNSodroskiJGFinziA.CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc Natl Acad Sci U S A2015;
112:E2687–94
124.
AnejaRRashadAALiHKalyana SundaramRVDuffyCBaileyLDChaikenI.Peptide triazole inactivators of HIV-1 utilize a conserved two-cavity binding site at the junction of the inner and outer domains of Env gp120. J Med Chem2015;
58:3843–58
125.
ChaikenIRashadAA.Peptide triazole inactivators of HIV-1: how do they work and what is their potential?Future Med Chem2015;
7:2305–10
126.
EgererLKiemHP,
von Laer D. C peptides as entry inhibitors for gene therapy. Adv Exp Med Biol2015;
848:191–209
127.
Cai L, Shi W, Liu K. Peptides and peptidomimetics as tools to probe protein-protein interactions?disruption of HIV-1 gp41 fusion core and fusion inhibitor design. Ekinci D (ed.) Biochemistry Rijeka, Croatia: InTech 2012, pp.39--64.
128.
VetrivelUSankarPNagarajanNSubramanianG.Peptidomimetics based inhibitor design for HIV–1 gp120 attachment protein. J Proteomics Bioinform2009;
2:481–84
129.
HoHTFanLNowicka-SansBMcAuliffeBLiCBYamanakaGZhouNFangHDickerIDalterioRGongYFWangTYinZUedaYMatiskellaJKadowJClaphamPRobinsonJColonnoRLinPF.Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol2006;
80:4017–25
130.
MadaniNSchönAPrinciottoAMLalondeJMCourterJRSoetaTNgDWangLBrowerETXiangSHKwonYDHuangCCWyattRKwongPDFreireESmithAB3rdSodroskiJ.Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure2008;
16:1689–701
131.
CassetFRouxFMouchetPBesCChardesTGranierCManiJCPugnièreMLauneDPauBKaczorekMLahanaRReesA.A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem Biophys Res Commun2003;
307:198–205
